Veradermics (MANE) investor relations material

Executive summary

• Focused on developing VDPHL01, an oral, non-hormonal treatment for pattern hair loss (PHL), with positive Phase 2/3 results in both male and female patients and ongoing late-stage clinical trials.

• Achieved positive topline results from open-label Phase 2 Study '207' for VDPHL01 in female pattern hair loss, showing rapid onset and consistent hair growth with strong tolerability.

• Completed IPO in Q1 2026, raising $269.1M, followed by a $414.3M public offering and $28.1M private placement in Q2 2026, totaling $472M raised in May 2026.

• No products approved or commercialized yet; all revenue to date from equity financings.

Financial highlights

• Net loss for Q2 2026 was $23.5M, up from $15.6M in Q2 2025; six-month net loss was $50.7M, up from $28.0M year-over-year.

• Operating expenses for Q2 2026 were $29.6M, up from $16.1M in Q2 2025, driven by increased R&D and G&A costs.

• R&D expenses were $18.6M and G&A expenses were $10.9M for Q2 2026, both up year-over-year.

• Cash, cash equivalents, and marketable securities totaled $819.9M as of June 30, 2026.

• Total assets as of June 30, 2026: $825.7M; total liabilities: $12.1M; stockholders' equity: $813.6M.

Outlook and guidance

• Existing cash resources expected to fund operations into 2030 based on current plans.

• Topline data from female PHL Phase 2/3 trial expected in H1 2027; topline data from male Phase 3 and 12-month data from Study '302' expected in 2H26.

• Anticipates continued operating losses and negative cash flows as clinical development and pre-commercial activities expand.